Biotechnology company āshibio has entered an exclusive licensing agreement with Mereo BioPharma for the monoclonal antibody, ...

The FDA has rejected vatiquinone, requesting that PTC run an additional study to prove the drug's efficacy prior to ...

In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration ...

The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for ...

Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo’s main rival in the GLP-1RA arena, Eli ...

Santen has signed an agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein for retinal ...

Viking's obesity pill VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in body ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Clinical trial data management is growing increasingly complex, with inefficiencies driving up costs and delaying timelines.

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.